Free Trial
NASDAQ:ABUS

Arbutus Biopharma Q1 2025 Earnings Report

Arbutus Biopharma logo
$3.18 -0.02 (-0.47%)
As of 12:46 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Arbutus Biopharma EPS Results

Actual EPS
-$0.13
Consensus EPS
-$0.09
Beat/Miss
Missed by -$0.04
One Year Ago EPS
N/A

Arbutus Biopharma Revenue Results

Actual Revenue
$1.76 million
Expected Revenue
$2.54 million
Beat/Miss
Missed by -$771.00 thousand
YoY Revenue Growth
N/A

Arbutus Biopharma Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Wednesday, May 14, 2025
Conference Call Time
7:30AM ET

Upcoming Earnings

Arbutus Biopharma's Q2 2025 earnings is scheduled for Thursday, August 7, 2025, with a conference call scheduled on Thursday, July 31, 2025 at 8:45 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Arbutus Biopharma Earnings Headlines

A new rule goes live in July — and the banks are quietly cashing in
A major change is quietly going into effect this July — and Wall Street is already positioning for it. Big Banks have found a way to use a new asset as if it were cash. Not stocks. Not bonds. Not even the U.S. dollar. They now trust this asset more than the traditional financial system itself.
See More Arbutus Biopharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Arbutus Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Arbutus Biopharma and other key companies, straight to your email.

About Arbutus Biopharma

Arbutus Biopharma (NASDAQ:ABUS), a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.

View Arbutus Biopharma Profile

More Earnings Resources from MarketBeat